The Src/c-Abl inhibitors increased the survival of iPSC-derived motor neurons from ALS patients in vitro, and siRNA knockdowns of c-Src or c-Abl prevented their degeneration. Here, ABL1 is linked to amyotrophic lateral sclerosis.